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Leber’s hereditary optic neuropathy (LHON) 
is the first mitochondrial disease defined, by Von 
Graefe in 1958 [1]. It is also the first maternally 
inherited disease discovered. Sudden painless 
central visual field loss in young patients espe-
cially in their 2nd/3rd decades is its classical pre-
sentation [1]. A progressive vision loss, especially 
with a typical cecocentral scotoma should arise a 
suspicion of this hereditary optic neuritis. Young 
males are effected the most (10-20% females) 
and a subacute vision loss in fellow eye develops 
soon during the disease. Stress, alcohol, smoking, 
caffeine, head trauma, menopause or postpartum 
estrogen are thought to be the mostly known trig-
gering factors [1, 2]. Exact diagnosis is by geneti-
cal testing for the mitochondrial mutations deter-
mined for LHON. Three point mutations within 
the mitochondrial genome (primary mutations); 
m.3460 G>A (MTND1) m.11778G>A (MTND4), 
and m.14484 T>C (MTND6), make up about 90% 
of all LHON cases.
Steroids and B12 replacement have no es-
tablished effect in the treatment of the disease 
but recent studies proved that antioxidant treat-
ments like Coenzyme Q10 may have a critical role 
for these cases by way of impairing live but inac-
tive neurons [2]. A short chain synthetic analog of 
Coenzyme Q10, called Idebenone has now a novel 
use for the treatment of this disease and nearly 
total recovery of patients can be observed in most 
of the patients during Idebenone treatment apart 
from the mutation type, besides a high rate of 
spontaneous recovery which can be seen by some 
good prognostic mutations of the disease [2-4].
In a pediatric case of Leber’s Hereditary Op-
tic Neuropathy (LHON), who was admitted to our 
ophthalmology clinic suffering from progressive 
loss of vision in her left eye, total visual recov-
ery was seen by use of Idebenon. On admission 
she had no history of trauma, no recent infection 
or no acute/chronic medications reported to be 
used. Her best corrected visual acuity (BCVA) 
was 20/20 on the right and 20/200 on left side. 
She had no RAPD, but impaired color vision and 
prolonged VEP p100 latency on left side. She had 
normal slit lamp and fundoscopic examination. 
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Visual field examination with 24-2 Humphrey pe-
rimeter revealed a left cecocentral scotoma (Fig. 
1, 2).
Although she had normal SD-OCT values for 
RNFL bilaterally, she had mild loss of ganglion cell 
layer bilaterally on GCIP analysis. Neuroimaging 
of the patient was normal; including cerebral, or-
bital and vertebral MRI scans. Pediatric neurol-
ogy department performed lumbar puncture and 
reported a normal opening pressure with normal 
cytology and oligoclonal band testing. Her blood 
tests including thrombophilia markers, infection 
and inflammatory parameters, ACE levels, vita-
min B12 levels were normal. She had been on high 
dose intravenous pulse steroid treatment for 3 
days (1000 mg/d) but no response was observed 
concerning visual acuity and visual field testing. 
During one month duration of the work up, vision 
on her both eyes deteriorated to the level of de-
tecting only hand motions, with a progression to 
total scotoma in both eyes on visual field testing. 
Ganglion cell layer analysis in SD-OCT revealed 
a progressive loss pointing out a mitochondrial 
neuropathy. Mutation analysis for LHON was per-
formed for the patient and immediate Idebenone 
treatment (p.o 900 mg/day) was started while 
waiting for the results of the genetic testing. On 
the first month of the treatment she experienced 
an increase in visual acuity to the level of 20/200 
on both eyes. At the sixth month of the treatment 
she had a total visual recovery on both eyes, with 
BCVA of 20/20 on each. Progressive improve-
ment in visual acuity testing was remarkable dur-
ing the Idebenone treatment (Fig. 3). Meanwhile, 
the patient was found to be positive for T14484C 
mitochondrial DNA mutation. 
Fig. 3. Improvement of visual field testing with IDEBENONE in  
a 6-month period
LHON was the first mitochondrial and mater-
nally inherited disease defined [1]. Young males 
are effected the most and simultaneous bilateral 
progressive vision loss is the main characteristic 
Fig. 1. Fundus photo and Humphrey 24-2 visual field test on the 
left eye
Fig. 2. Fundus photo and Humphrey 24-2 visual field test on the 
right eye
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of the disease. Novel use of Idebenone for LHON 
treatment in adults has been the topic of many 
studies but studies establishing its therapeutic 
role and dosage in pediatric population are lim-
ited [2-4]. Idebenone is a synthetic ubiquinone 
analogue which carries a short-chain. It assists 
the transfer of electrons from complexes I and II 
to complex III [5]. Idebenone is different from co-
enzyme Q10 (CoQ10) since it contains a greater 
bioavailability due to its less lipophilic tail help-
ing it to penetrate the blood – brain barrier and 
mitochondrial membrane easily [6]. The efficacy 
of idebenone was investigated in the RHODOS 
study, which is a randomized, double-blinded, 
placebo-controlled study. It included 82 patients 
with LHON disease that carried either one of the 
three LHON primary mtDNA mutations. Patients 
were grouped in a 2:1 ratio in favor of Idebenone, 
and Idebenone with a dose of 300 mg three times 
a day was used during a treatment period of 24 
weeks [7, 8]. Besides this RHODOS study, the vi-
sual support of idebenone treatment was inves-
tigated in a retrospective review of 103 patients 
who were treated with idebenone at different 
doses and at variable treatment durations [9]. 
Both these studies put through a visual benefit in 
patients on Idebenone treatment and the benefit 
of Idebenone was more in cases who used Ide-
benone earlier during the disease- before  func-
tionally suppressed but live ganglion cells are not 
damaged irreversibly. Idebenone has been ap-
proved by the European Medicine Agency (EMA) 
to treat LHON and postmarketing studies are cur-
rently underway to collect additional safety and 
efficacy data [5]. 
Although the rate of spontaneous recovery is 
reported to be high in LHON cases with 14484 
mutation, the presented case aims to put through 
the supportive role of Idebenone in pediatric cas-
es of LHON, too. This role must be investigated in 
further studies.
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